- Home
- IPA vs PRLD Comparison
IPA vs PRLD Comparison
Compare IPA & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPA
- PRLD
- Stock Information
- Founded
- IPA 1983
- PRLD 2016
- Country
- IPA United States
- PRLD United States
- Employees
- IPA N/A
- PRLD N/A
- Industry
- IPA Biotechnology: Pharmaceutical Preparations
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- IPA Health Care
- PRLD Health Care
- Exchange
- IPA Nasdaq
- PRLD Nasdaq
- Market Cap
- IPA 46.0M
- PRLD 48.6M
- IPO Year
- IPA 2017
- PRLD 2020
- Fundamental
- Price
- IPA $1.28
- PRLD $0.78
- Analyst Decision
- IPA Strong Buy
- PRLD Strong Buy
- Analyst Count
- IPA 2
- PRLD 2
- Target Price
- IPA $4.00
- PRLD $4.50
- AVG Volume (30 Days)
- IPA 5.1M
- PRLD 224.4K
- Earning Date
- IPA 07-28-2025
- PRLD 08-11-2025
- Dividend Yield
- IPA N/A
- PRLD N/A
- EPS Growth
- IPA N/A
- PRLD N/A
- EPS
- IPA N/A
- PRLD N/A
- Revenue
- IPA $16,581,105.00
- PRLD $7,000,000.00
- Revenue This Year
- IPA $4.67
- PRLD N/A
- Revenue Next Year
- IPA $14.15
- PRLD N/A
- P/E Ratio
- IPA N/A
- PRLD N/A
- Revenue Growth
- IPA 1.34
- PRLD N/A
- 52 Week Low
- IPA $0.27
- PRLD $0.61
- 52 Week High
- IPA $1.31
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- IPA 75.91
- PRLD 42.16
- Support Level
- IPA $1.00
- PRLD $0.77
- Resistance Level
- IPA $1.15
- PRLD $0.84
- Average True Range (ATR)
- IPA 0.13
- PRLD 0.07
- MACD
- IPA 0.02
- PRLD -0.02
- Stochastic Oscillator
- IPA 94.38
- PRLD 16.04
About IPA ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several subsidiaries in North America and Europe.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.